Edwards Lifesciences Corporation $EW Stock Holdings Lifted by California State Teachers Retirement System

California State Teachers Retirement System increased its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 9,187.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 80,962,062 shares of the medical research company's stock after acquiring an additional 80,090,362 shares during the quarter. California State Teachers Retirement System owned approximately 14.06% of Edwards Lifesciences worth $7,323,828,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in EW. BlackRock Inc. acquired a new stake in Edwards Lifesciences in the second quarter worth $5,318,092,000. Bank of New York Mellon Corp bought a new position in Edwards Lifesciences in the 2nd quarter worth about $1,274,082,000. Norges Bank acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $803,686,000. Bank of America Corp DE bought a new stake in shares of Edwards Lifesciences during the second quarter valued at approximately $605,397,000. Finally, Deutsche Bank AG bought a new stake in shares of Edwards Lifesciences during the second quarter valued at approximately $516,552,000. Institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Price Performance

NYSE:EW opened at $86.73 on Wednesday. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The business's 50-day moving average price is $89.63 and its 200 day moving average price is $85.70. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $96.29. The firm has a market cap of $49.94 billion, a P/E ratio of 49.85, a PEG ratio of 2.36 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts' consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The company had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.70 billion. During the same period in the prior year, the company earned $0.67 EPS. Edwards Lifesciences's revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, sell-side analysts predict that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. JPMorgan Chase & Co. increased their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an "overweight" rating in a report on Friday, July 24th. Citigroup lifted their target price on Edwards Lifesciences from $101.00 to $110.00 and gave the company a "buy" rating in a research note on Wednesday, July 8th. Mizuho boosted their price target on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 15th. UBS Group initiated coverage on Edwards Lifesciences in a report on Tuesday, July 28th. They set a "buy" rating and a $110.00 price target on the stock. Finally, TD Cowen reiterated a "buy" rating on shares of Edwards Lifesciences in a research report on Tuesday, July 21st. Seventeen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of "Moderate Buy" and an average target price of $100.27.

Insider Activity

In other news, VP Daniel J. Lippis sold 619 shares of the business's stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the sale, the vice president directly owned 40,034 shares of the company's stock, valued at $3,684,329.02. The trade was a 1.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 544 shares of the company's stock in a transaction on Monday, August 31st. The shares were sold at an average price of $91.06, for a total value of $49,536.64. Following the sale, the senior vice president directly owned 14,868 shares of the company's stock, valued at approximately $1,353,880.08. This represents a 3.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 5,045 shares of company stock worth $457,749. Insiders own 0.31% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.